Indeed, recent phase clinical 3 trials indicate that suppression of IL-1β signalling with the monoclonal antibody canakinumab markedly reduced the risk of major adverse cardiovascular events2, highlighting the important role of IL-1β in cardiovascular disease. This evidence concerns the gene IL1B and cardiovascular disorder.